Nevertheless, SLGT2 inhibitors have shown significant decreases in blood glucose and HbA1c levels regardless of insulin amount or sensitivity with no weight gain or hypoglycemia, which are common side effects in conventional antidiabetic drugs [145,146]. Here, INS is linked to Hypoglycemia.